Russia’s flagship two-shot vaccine Sputnik V has shown 91.6 per cent efficacy against symptomatic Covid-19 in clinical trials, a Lancet peer review has confirmed, bringing the global total of vaccines whose efficacy is confirmed to be higher than 90 per cent to three.
经《柳叶刀》(Lancet)同行评审确认，俄罗斯的旗舰疫苗、需要接种两剂的“卫星-V”(Sputnik V)在临床试验中对预防有症状新型冠状病毒肺炎（COVID-19，即2019冠状病毒病）的有效率达到91.6%，从而使manbetx app苹果 有效率经确认高于90%的疫苗总数增加到三种。
您已阅读9%（402字），剩余91%（4082字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。